Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 15/20 | 0.45 |
| ▸ | UBA3 | Q8TBC4 | 15/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SAE1 | Q9UBE0 | 13/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 13/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805417 | 0.91 | NAE1 (0.49) | NAE1UBA3GSK3BSAE1UBA2 | |
| SCHEMBL10283691 | 0.89 | NAE1 (0.52) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL783619 | 0.86 | NAE1 (0.61) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL10283339 | 0.84 | NAE1 (0.62) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805407 | 0.82 | NAE1 (0.61) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805369 | 0.81 | NAE1 (0.46) | NAE1UBA3SAE1UBA2ADORA3 | |
| SCHEMBL805377 | 0.79 | NAE1 (0.49) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805393 | 0.78 | NAE1 (0.49) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805390 | 0.78 | NAE1 (0.48) | NAE1UBA3SAE1UBA2 | |
| SCHEMBL805382 | 0.77 | NAE1 (0.43) | NAE1UBA3SAE1UBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885GSK3B 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.